Brind.

Exelixis's CABOMETYX received FDA approval for neuroendocrine tumors (NET) on September 5, 2025.

3 reports, 2 independent Updated Sep 5
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Exelixis's CABOMETYX received FDA approval for neuroendocrine tumors (NET) on September 5, 2025.

Who's involved

What this event is mainly about
NETExelixisFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA approved CABOMETYX for NET.1 source
  2. FDA granted label expansion for Cabometyx for NET.1 source
  3. Exelixis's Cabometyx received FDA label expansion approval and faces competition from Merck's Keytruda and Pfizer's Inlyta.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyExelixis, Inc. (EXEL): A Bull Case Theory We came across a bullish thesis on Exelixis, Inc. on Investing With Purpose’s. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.'s
  • ZacksWhy Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report? It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 3.8% in that time frame, outperforming
  • ZacksCabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of renal